Hester Biosciences Complete Financial Statements
In FY2026, Hester Biosciences (HESTERBIO) reported revenue ₹102 Cr, net profit ₹17 Cr and EPS ₹19.45, with a net profit margin of 16.7% and ROE of 4.7%. Full financial statements from FY2015 to FY2026 (12 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Explore HESTERBIO value investing to estimate fundamental worth using multiple valuation models.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
HESTERBIO Revenue, Net Profit & EBITDA — Year-on-Year Growth
HESTERBIO YoY (Mar 2025 vs Mar 2026) — revenue +34.2%, net profit +750.0%, EBITDA +157.1%, expenses +4.8%. Review HESTERBIO earnings multiple to evaluate earnings-based valuation against sector peers.
HESTERBIO Income Statement — Revenue, EBITDA & Net Profit
Hester Biosciences revenue ₹102 Cr, EBITDA ₹36 Cr, net profit ₹17 Cr, EPS ₹19.45 (2026) — net profit margin 16.7%. For live price, earnings ratios and company overview, see Hester Biosciences screener.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 | Sept 2021 | Mar 2021 | Jun 2021 | Dec 2021 | Sept 2020 | Mar 2020 | Jun 2020 | Dec 2020 | Sept 2019 | Mar 2019 | Jun 2019 | Dec 2019 | Sept 2018 | Jun 2018 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102 | 83 | 76 | 88 | 79 | 87 | 84 | 84 | 72 | 76 | 71 | 90 | 69 | 78 | 64 | 55 | 81 | 64 | 67 | 63 | 59 | 54 | 48 | 41 | 58 | 45 | 58 | 45 | 51 | 43 | 41 | 46 |
| Expenses | 66 | 59 | 63 | 61 | 60 | 65 | 63 | 65 | 58 | 57 | 56 | 74 | 57 | 60 | 46 | 43 | 56 | 45 | 48 | 43 | 41 | 38 | 36 | 28 | 36 | 33 | 35 | 27 | 30 | 28 | 25 | 26 |
| EBITDA | 36 | 24 | 14 | 26 | 20 | 22 | 21 | 20 | 14 | 19 | 15 | 17 | 12 | 18 | 18 | 12 | 25 | 19 | 19 | 19 | 18 | 16 | 12 | 13 | 22 | 12 | 23 | 18 | 21 | 16 | 16 | 21 |
| Operating Profit Margin % | 34.00% | 17.00% | 23.00% | 27.00% | 23.00% | 23.00% | 20.00% | 21.00% | 8.00% | 19.00% | 17.00% | 16.00% | 15.00% | 17.00% | 18.00% | 15.00% | 25.00% | 28.00% | 26.00% | 28.00% | 27.00% | 30.00% | 16.00% | 30.00% | 37.00% | 25.00% | 33.00% | 39.00% | 41.00% | 36.00% | 37.00% | 44.00% |
| Depreciation | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 3 | 4 | 3 | 5 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 2 | 3 |
| Interest | 5 | 2 | 6 | 2 | 2 | 6 | 7 | 5 | -4 | 8 | 1 | 3 | 2 | 3 | 2 | 2 | 4 | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 1 | 3 | 2 | 3 | 2 | 1 | 1 |
| Profit Before Tax | 25 | 17 | 4 | 20 | 14 | 12 | 10 | 11 | 13 | 7 | 8 | 9 | 6 | 10 | 11 | 6 | 16 | 15 | 14 | 15 | 12 | 11 | 6 | 8 | 18 | 7 | 17 | 13 | 15 | 10 | 12 | 17 |
| Tax | 9 | 3 | 2 | 3 | 4 | 4 | 4 | 3 | 2 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 2 | 3 | 5 | 1 | 3 | 5 | 3 | 5 | 4 | 4 |
| Net Profit | 17 | 14 | 2 | 17 | 9 | 8 | 6 | 8 | 11 | 4 | 6 | 7 | 4 | 7 | 9 | 4 | 12 | 11 | 10 | 11 | 8 | 7 | 5 | 5 | 13 | 6 | 14 | 8 | 12 | 6 | 8 | 12 |
| Earnings Per Share (₹) | 19.45 | 16.85 | 1.82 | 20.33 | 10.94 | 9.86 | 7.52 | 8.80 | 13.41 | 4.75 | 6.72 | 7.89 | 4.73 | 7.77 | 10.59 | 4.19 | 14.29 | 13.08 | 11.87 | 12.95 | 9.79 | 7.86 | 5.60 | 5.94 | 15.13 | 7.30 | 15.87 | 9.51 | 14.05 | 6.93 | 9.75 | 14.62 |
HESTERBIO Balance Sheet — Assets, Liabilities & Shareholders' Equity
HESTERBIO total assets ₹678 Cr, total equity ₹360 Cr, total liabilities ₹ Cr (2026) — ROE 4.7%.
| Particulars | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| Total Assets | 678 | 653 | 662 | 670 | 562 | 411 | 387 | 300 | 244 | 213 | 186 | 161 |
| Current Assets | 209 | 195 | 215 | 228 | 195 | 162 | 159 | 143 | 98 | 80 | 74 | 60 |
| Fixed Assets | 421 | 233 | 240 | 259 | 237 | 133 | 142 | 145 | 110 | 103 | 65 | 60 |
| Capital Work in Progress | 0 | 183 | 171 | 149 | 82 | 109 | 74 | 7 | 32 | 21 | 37 | 33 |
| Investments | 73 | 34 | 30 | 25 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 203 | 221 | 237 | 222 | 169 | 170 | 148 | 102 | 89 | 85 | 68 |
| LIABILITIES | ||||||||||||
| Total Liabilities | ||||||||||||
| Current Liabilities | 158 | 202 | 254 | 233 | 198 | 114 | 97 | 70 | 44 | 48 | 41 | 38 |
| Non-Current Liabilities | ||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||
| Total Equity | 360 | 327 | 303 | 289 | 267 | 236 | 207 | 181 | 145 | 127 | 106 | 88 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves & Surplus | 352 | 306 | 283 | 271 | 252 | 220 | 193 | 169 | 132 | 113 | 93 | 76 |
HESTERBIO Cash Flow Statement — Operating, Investing & Financing
Hester Biosciences operating cash flow ₹65 Cr, investing ₹-20 Cr, financing ₹-52 Cr, net cash flow ₹-7 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 65 | 48 | 24 | 9 | 58 | 37 | 47 | 38 | 35 | 19 | 20 |
| Investing Activities | -20 | -23 | -77 | -117 | -42 | -73 | -21 | -26 | -30 | -13 | -21 |
| Financing Activities | -52 | -26 | 42 | 112 | -18 | 19 | 3 | -11 | 2 | -7 | 7 |
| Net Cash Flow | -7 | 0 | -12 | 4 | -2 | -17 | 28 | 1 | 6 | -1 | 5 |